EDM钀ラ攢姹傝亴鎷涜仒QQ缇? http://liangssw.com/bozhu/14836.html

感染SARS-CoV-2后恢复期患者中，大约有一半在感染后的2个月内持续出现症状，并且肺功能下降，这种情况即使在合并症很少的年轻人群SARS-CoV-2感染康复期内也很常见。

Clinicalcharacteristicsandlungfunction

Symptomaticatfollow-up(n=)Asymptomaticatfollow-up(n=)p-valueValueRangeValueRangeClinicalcharacteristics?Ageyears47±–±–.47?Male41(36%)67(50%)0.06?Follow-updays66±–±–#0.07?Symptoms??Atinfectionn3.7±1.51–73.1±1.51–60.01*??Atfollowupn1.3±0.51–.Clinicalcourse?Outpatient97(86%)(95%)0.01*?Inpatient15(13%)5(4%)0.01*?Intensivecare1(1%)1(1%)0.99Comorbidities?Totaln0.3±0.60–20.2±0.50–20.49?Respiratory14(12%)10(8%)0.28??Asthma8(7%)6(5%)0.41??Sarcoidosis1(1%)00.46??Other5(4%)4(3%)0.74?Cardiovascular8(7%)14(11%)0.38??Hypertension6(5%)11(8%)0.45??Other2(2%)3(2%)0.99?Diabetes4(4%)2(2%)0.41Therapy(atinfection)?None(93%)(98%)0.05*?Steroids2(2%)00.21?Antiviral2(2%)2(2%)0.99?Antibacterial3(3%)1(1%)0.33?Antifungal1(1%)00.46?Anticoagulation1(1%)00.46Therapy(atfollow-up)?Inhaledsteroids7(6%)1(1%)0.05*?Bronchodilators6(5%)00.01*Lungfunction(atfollow-up)?FEV1/FVC%85±–±–.26?FEV1%pred96±–±–.01*?MEF50%pred±–298±–.98?VC%pred96±–±–.01*?TLC%pred±–135±–.51?RV/TLC%38±–±–.27?sRtot%pred±–±–.24?TLCO?%pred83±–88±–.05*

Dataarepresentedasn(%)ormean±sd,unlessotherwiseindicated.FEV1:forcedexpiratoryvolumein1?s;(F)VC:(forced)vitalcapacity;MEF50:maximumexpiratoryflowat50%ofFVC;TLC:totallungcapacity;RV:residualvolume;sRtot:specifictotalairwayresistance;TLCO:transferfactorofthelungforcarbonmonoxide.#:onepatientunderwentbodyplethysmographyonthedayofconfirmedinfection;?:TLCOwasavailableinpatients(65%).*:statisticallysignificantp0.05(t-test).

文章信息：

ResidualsymptomsandlowerlungfunctioninpatientsrecoveringfromSARS-CoV-2infection

FrederikTrinkmann,MichaelMüller,AlexandraReif,NicolasKahn,MichaelKreuter,FranziskaTrudzinski,MonikaEichinger,Claus-PeterHeussel,FelixJ.F.HerthfortheLungNetworkRhine-Neckar-Region

EuropeanRespiratoryJournal:;

DOI:10./.-

点击左下阅读原文

扫码